¾ÆÁ¨´Ù
ÇÁ·Î±×·¥
Âü°¡ÀÚ ¸®½ºÆ®
̵̧ȍ
½ºÆù¼/Àü½Ã±â¾÷
½ºÆù¼
Àü½Ã±â¾÷ Ç÷ξîÇ÷£
°³ÃÖÁö
Æ÷½ºÅÍ
¹®ÀÇ
Âü°¡½Åû
ÄÁÆÛ·±½º ÇÁ·Î±×·¥
°øÇÐ ½ºÆ®¸²
Display of Biologics
¹ÙÀÌ¿À·ÎÁ÷½ºÀÇ µð½ºÇ÷¹ÀÌ
Engineering Antibodies
Ç×ü °øÇÐ
Machine Learning Part 2
±â°èÇнÀ ÆÄÆ® 2
Ÿ°Ù ½ºÆ®¸²
Antibody-Based Therapies
Ç×ü ±â¹Ý ÀǾà
Emerging Targets
½Å±Ô Ÿ°Ù
Membrane Protein Targets
¸·´Ü¹éÁú Ÿ°Ù
ÀÌÁ߯¯À̼º ½ºÆ®¸²
Safety & Efficacy
¾ÈÀü¼º¡¤À¯È¿¼º
Advancing Multispecifics
´ÙÁß Æ¯À̼º Ç×üÀÇ Áøº¸
Engineering Bispecifics
ÀÌÁ߯¯À̼ºÇ×ü °øÇÐ
¸é¿ªÄ¡·á ½ºÆ®¸²
Immunoengineering
¸é¿ª °øÇÐ
Innovative CAR Therapy
Çõ½ÅÀûÀÎ CAR ¿ä¹ý
Next-Gen Immunotherapies
Â÷¼¼´ë ¸é¿ªÄ¡·á
ºÐ¼®¹ý ½ºÆ®¸²
Optimisation & Developability
ÃÖÀûÈ¡¤°³¹ß °¡´É¼º
Analytical Characterisation
ºÐ¼®¹ý Ư¼º Æò°¡
Protein Stability & Formulation
´Ü¹éÁú ¾ÈÁ¤¼º¡¤Á¦Çü
¹ßÇö ½ºÆ®¸²
Leveraging Data Science
µ¥ÀÌÅÍ »çÀ̾𽺠Ȱ¿ë
Optimising Expression
¹ßÇö ÃÖÀûÈ
Developing Workflows
¿öÅ©ÇÃ·Î¿ì °³¹ß
±â°èÇнÀ ½ºÆ®¸²
Intro to Machine Learning
±â°èÇнÀ ÀÔ¹®
Machine Learning Part 1
±â°èÇнÀ ÆÄÆ® 1
Machine Learning Part 2
±â°èÇнÀ ÆÄÆ® 2
Á¾¾ç ½ºÆ®¸²
Antibody-Based Therapies
Ç×ü ±â¹Ý ÀǾà
Engineering ADCs
ADC °øÇÐ
Next-Gen Immunotherapies
Â÷¼¼´ë ¸é¿ªÄ¡·á